$AZN plans to start its 30,000-person Phase 3 trial in July, while $PFE CEO Albert Bourla said on a Thursday call that the pharma giant is planning for a study of its vaccine candidate that would enroll 20,000 or 30,000 participants.  https://t.co/rzXakVXMmQ